SEC Form 4 · accession 0000899243-17-000472
Dicerna Pharmaceuticals Inc · DRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James B Weissman
Officer — Chief Business Officer
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001399529
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $2.97 | Jan 3, 2017 | A | 75,000 | A | — | Jan 3, 2027 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date.
Remarks
Exhibit 24.1 - Power of Attorney